Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The adrenal cancer research network "COMETE" is federating French research on rare adrenal cancers. COMETE achieved major breakthroughs in the molecular characterization of adrenocortical carcinomas (ACC) and malignant pheochromocytomas/paragangliomas (MPP). Recently, COMETE successfully derived potential biomarkers for prognosis, theranostic and follow-up. Those biomarkers have been retrospectively validated. However the benefit for patients in real life conditions is not yet established.
Main objective : to implement COMETE biomarkers as a routine standard of care for adrenal cancer.
The primary end point is double :
Secondary objective : to estimate the impact of COMETE biomarkers on patients management.
Secondary endpoints :
Full description
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
450 participants in 2 patient groups
Loading...
Central trial contact
Christelle AUGER, Chef de projet; Guillaume Assie, Pr
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal